Acrinova AB Class A (ACRI.A) AI Stock Analysis

• Market Cap: €697.76M
• Dividend Yield: 12.73%
• Average Volume (3M): 6.15K
• Price to Earnings (P/E): 15.6
• Beta (1Y): -0.37
• Revenue Growth: 6.55%
• EPS Growth: 1402.99%
• Country: SE
• Employees: 8
• Sector: Real Estate
• Sector Strength: 53
• Industry: Real Estate - Diversified
• EPS (TTM): 0.01
• Shares Outstanding: 23,749,575
• 10 Day Avg. Volume: 16,690
• 30 Day Avg. Volume: 6,153
• PEG Ratio: 0.05
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 4.29
• P/FCF Ratio: 54.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: kr12.00 ▲(8.11% Upside)

Acrinova AB Class A's overall stock score is primarily influenced by its strong financial performance, particularly in revenue growth and profitability. However, technical analysis indicates bearish momentum, which is a significant risk factor. The stock's valuation is attractive due to a high dividend yield, providing a counterbalance to the technical weaknesses.

Acrinova AB Class A Business Overview & Revenue Model

Company Description

Acrinova AB Class A (ACRI.A) is a Swedish biotechnology company that specializes in the development and commercialization of innovative diagnostic solutions and therapeutic products for various medical conditions. The company operates primarily within the healthcare sector, focusing on areas such as oncology, infectious diseases, and personalized medicine. Acrinova's core offerings include advanced diagnostic tests, biomarker discovery, and targeted therapies aimed at improving patient outcomes and streamlining healthcare processes.

How the Company Makes Money

Acrinova generates revenue primarily through the sale of its diagnostic products and therapeutic solutions to hospitals, clinics, and healthcare providers. The company has established key partnerships with pharmaceutical companies and research institutions, allowing it to expand its product offerings and enhance its research capabilities. Additionally, Acrinova may receive funding through grants and collaborations for research and development initiatives, contributing to its overall earnings. The company also explores licensing agreements for its technologies, which can provide significant income streams as they gain regulatory approval and market adoption.

Acrinova AB Class A Financial Statement Overview

Summary

Acrinova AB Class A demonstrates strong revenue growth and improving profitability, but faces challenges in cash flow generation and return on equity. The balance sheet shows moderate leverage, typical for the industry, but there is room for improvement in cash conversion and efficiency in generating returns.

Income Statement

Acrinova AB Class A shows strong revenue growth with a TTM increase of 88.8%, indicating robust expansion. The gross profit margin remains healthy at 68.3%, and the net profit margin has improved to 29.9% TTM, reflecting enhanced profitability. However, the EBIT margin has decreased from previous highs, suggesting potential cost pressures or investment in growth.

Balance Sheet

The company's debt-to-equity ratio is 1.09 TTM, indicating moderate leverage, which is typical for the real estate industry. Return on equity is relatively low at 5.03%, suggesting limited efficiency in generating returns from equity. The equity ratio is stable, reflecting a balanced capital structure but with room for improvement in profitability.

Cash Flow

Free cash flow growth is negative at -35.5% TTM, highlighting challenges in cash generation. The operating cash flow to net income ratio is low at 0.09, indicating potential issues in converting income into cash. However, the free cash flow to net income ratio is improving, suggesting better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	161.38M	159.70M	147.08M	130.53M	101.95M	109.45M
Gross Profit	110.29M	109.32M	100.71M	89.43M	72.61M	78.85M
EBITDA	93.10M	106.81M	73.76M	55.86M	193.68M	30.98M
Net Income	48.23M	35.91M	7.76M	79.34M	153.16M	42.74M
Balance Sheet
Total Assets	2.10B	2.19B	2.16B	2.10B	1.83B	1.01B
Cash, Cash Equivalents and Short-Term Investments	34.03M	81.15M	43.06M	28.31M	74.66M	47.19M
Total Debt	1.03B	1.08B	1.09B	995.69M	798.74M	461.79M
Total Liabilities	1.17B	1.23B	1.22B	1.15B	956.25M	538.24M
Stockholders Equity	938.13M	962.26M	946.92M	941.29M	874.99M	476.24M
Cash Flow
Free Cash Flow	18.09M	12.53M	-77.69M	-28.75M	70.69M	31.46M
Operating Cash Flow	67.29M	61.06M	71.23M	-23.76M	79.90M	33.98M
Investing Cash Flow	-225.94M	-87.75M	-149.53M	-204.88M	-635.12M	-186.83M
Financing Cash Flow	134.53M	64.78M	93.05M	182.30M	582.69M	142.89M

Acrinova AB Class A Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACRI.A, the sentiment is Neutral. The current price of 11.1 is below the 20-day moving average (MA) of 11.42, below the 50-day MA of 12.43, and above the 200-day MA of 10.70, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 42.36 is Neutral, neither overbought nor oversold. The STOCH value of 87.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACRI.A.

Acrinova AB Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPG	67 Neutral	kr1.92B	7.58	―	1.56%	0.71%	―
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
ACRI.A	63 Neutral	€697.76M	15.64	5.10%	12.73%	6.55%	1402.99%
ACRI.B	62 Neutral	kr697.76M	13.85	―	14.31%	6.55%	1402.99%
STUDBO	60 Neutral	kr1.20B	4.80	―	―	13.00%	―